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The incidence of non-Hodgkin’s lymphoma (NHL) is increasing in
most parts of the world. A comparison of cancer registry informa-
tion between 1982 and 1992 (Parkin et al, 1992, 1997) indicates
that this increase is occurring at an average annual rate of 4–5%
each year, implying a doubling of NHL incidence every 20 years.
This upward trend is observed in all geographical regions covered
by cancer registration, and is not restricted to any particular age
group or sex, or to predominantly rural or urban areas. The reason
for the increase has attracted much speculation but there is no clear
explanation for it.
The changing diagnostic classification of NHL cannot explain
recent increases that have occurred (Cartwright, 1992), while
AIDS-related lymphomas represent only a small proportion of all
lymphomas in most regions (Rolland-Portal et al, 1997). Other
explanations offered for the observed trends in NHL include
increasing population exposure to pesticides, organic solvents and
hair dyes, but none of these is well supported by the evidence.
Recent interest has focused attention on solar ultraviolet
radiation as a possible cause of the increasing incidence for 
both melanoma of the skin and NHL (Cartwright et al, 1994;
McMichael and Giles, 1996). To investigate this hypothesis
further we have studied second primary cancers in NHL patients
registered with the New South Wales (NSW) Central Cancer
Registry in Australia. This registry was considered to be particu-
larly suitable because of its size and period of time in operation 
(24 years), and because NHL and melanoma incidence rates in
New South Wales are among the highest in the world (Parkin et al,
1997). Our a priori hypothesis was that if sunlight was related to
the aetiology of NHL we would expect an excess of melanoma of
the skin among patients with NHL.
METHODS
The NSW Central Cancer Registry is a population-based registry
which first reported cancer statistics for the year 1972. The
registry covers the population of NSW of over 6 000 000, of
whom approximately two-thirds live in the cities of Sydney,
Newcastle and Wollongong. Approximately 25% of the population
are migrants to Australia. The prime source of cancer data is the
compulsory notification form completed by hospital staff for each
cancer case in every public and private hospital. In addition, each
department of radiation oncology must notify each cancer case
when first treated in the department. Pathology laboratories must
also send copies of all reports of a diagnosis of cancer. Each
person is given a unique identification number when first regis-
tered. Subsequent primary cancers are registered and linked to the
first through the identification number. Tumour site was coded
according to the International Classification of Disease, Ninth
Revision (ICD-9). Population census data were provided by the
Australian Bureau of Statistics which publishes annual estimates of
the mid-year resident population based on a quinquennial census.
From 1972 to 1995 a total of 15 330 NHL patients (ICD-9 codes
200, 202) were registered in NSW. To avoid detection bias in
cancers present at the time of NHL diagnosis, the follow-up period
did not start until 3 months after NHL diagnosis. A total of 2878
cases either died or were reported as having a second primary
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these left a study population of 12 452 patients. For each patient
the length of time at risk of a subsequent cancer was calculated
from 3 months after the date of NHL diagnosis to the first of (i) the
date of diagnosis of second neoplasm, (ii) date of death, or (iii) the
end of the study follow-up (31 December 1995), whichever was
earliest. Mortality follow-up was conducted through linkage to the
NSW register of deaths and the Australian National Death Index.
To assess any possible excess of second primary neoplasms in
the cohort of primary NHL, we compared the observed number of
neoplasms to the expected number derived from the age- and sex-
specific cancer incidence rates of the NSW population for the years
1972–1995, after excluding the expected number of NHL
Standardized incidence ratios (SIR) adjusted for age, year, sex and
country of birth were calculated using indirect standardization
methods. Exact confidence intervals (CI) around the SIR were
calculated assuming a Poisson distribution for the observed number
of neoplasms. This analysis was conducted for all neoplasms
combined and also for specific cancer sites. The NSW Cancer
Registry does not routinely register non-melanocytic skin cancers.
RESULTS
The 12 452 patients contributed 54 308 person-years of follow-up
time during which there occurred 705 second primary neoplasms.
As might be expected, those with a second neoplasm were more
likely to be male, to be older and to be diagnosed earlier in the
study period than those who were free of a second neoplasm
(Table 1). The two groups were comparable with respect to their
countries of origin, with approximately 75% being born in
Oceania (mainly Australia and New Zealand). The next largest
group comprised immigrants from northern and western Europe,
the majority of whom were from the UK and Ireland. Nearly all
those who had migrated from the Mediterranean region had been
born in Italy, Greece or Malta. The majority of patients from
Central/Eastern Europe were from Poland, Hungary and former-
Yugoslavia.
The observed 705 second neoplasms in NHL patients were
compared to the number that would have been expected given the
demographic structure of the study population and the local cancer
incidence rates during the study period (Table 2). The expected
number of second neoplasms was 592.99 (SIR = 1.19, 95% CI
1.10–1.28). This 19% increase in the observed cancer incidence
was mainly due to over a twofold excess of melanoma of the skin
based on 93 cases (SIR = 2.38, 95% CI 1.92–2.91). However, a
significant (P < 0.05) increase in risk of a cancer was also
observed at five other sites. There was over a twofold increase in
cancer of the lip based on 17 observed cases (SIR = 2.74, 95% CI
1.59–4.38), and a similar increase in tongue cancer based on eight
cases (SIR = 2.53, 95% CI 1.09–4.99). There was over a threefold
excess in soft tissue sarcomas based on 11 cases (SIR = 3.61, 95%
CI 1.80–6.45), and a 64% excess of bladder cancer was observed
based on 44 cases (SIR = 1.64, 95% CI 1.19–2.21). Also, there was
a sizeable increase in thyroid cancer based on nine cases (SIR =
3.42, 95% CI 1.56–6.49). The observed and expected numbers of
the remaining cancer sites were all roughly similar to each other. A
25% excess of colon cancer based on 80 cases (SIR = 1.25, 95%
CI 0.99–1.55), and a deficit of pancreatic cancer based on eight
cases (SIR = 0.45, 95% CI 0.20–0.90) may be due to chance given
that over 30 comparisons were made.
The six cancer sites that were observed in excess were analysed
in more detail after stratifying for sex, age, year of diagnosis, time
period after NHL diagnosis and geographic region of birth (Table
3). The excess of melanoma of the skin was observed equally
among men and women, over all age groups, over the whole of the
study period, and also in all time periods after diagnosis of NHL.
However, it was restricted to those born in Oceania and immigrants
from North/West Europe and was not found among immigrants
from Mediterranean Europe or Central/Eastern Europe (expected
2.7 cases). Stratified analysis for the other five cancer sites did not
indicate any strong trends although numbers were small.
DISCUSSION
Our analysis of more than 12 000 primary NHL, and over 700
subsequent second neoplasms, revealed a 19% increased risk of all
second cancers combined, which was due to increased risks for
melanoma of the skin and cancers of the lip, tongue, bladder and
thyroid, and also soft tissue sarcomas.
A systematic review of all previous studies investigating second
cancers after NHL has recently been conducted (Boffetta et al,
1999). This indicated that NHL patients experienced large excess
risks of acute non-lymphocytic leukaemia (ANLL), Hodgkin’s
disease and melanoma of the skin, and smaller increases for lung,
kidney and bladder cancers. The risk of ANLL and bladder cancer
was considered to be related to chemotherapy, especially use of
cyclophosphamide for bladder cancer (Travis et al, 1995), and use
of prednimustine and mechlorethamine or procarbazine for ANLL
(Travis et al, 1994). Radiotherapy use was associated with risk of
both ANLL and lung cancer. Melanoma of the skin was not associ-
ated with NHL treatment.
Similar to previous reports, the observed increase in bladder
cancer in our study is likely to be due to initial treatment of the
NHL with cyclophosphamide. Cyclophosphamide was used
consistently in combination chemotherapy for NHL in Australia
over the period of diagnosis of the cases. Also, given the known
epidemiology of thyroid cancer, the observed excess at this site is
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Table 1 Characteristics of NHL patients, New South Wales, 1972–1995
Free of second Second neoplasm
neoplasm (n = 11 747) (n = 705)
Sex
Male 6297 (54%) 427 (61%)
Female 5450 (46%) 278 (39%)
Age at diagnosis of NHL
<  51 2979 (25%) 88 (12%)
51–64 3384 (29%) 274 (39%)
65–70 1922 (16%) 134 (19%)
71+ 3462 (30%) 209 (30%)
Year of diagnosis of NHL
Before 1980 2393  (20%) 201 (29%)
1980–1984 2189 (19%) 182 (26%)
1985–1989 2899 (25%) 213 (30%)
After  1990 4266 (36%) 109 (15%)
Country of birth
Oceania 9004 (77%) 534 (76%)
North/West  Europe 1192 (10%) 80 (11%)
Mediterranean  Europe 452 (4%) 26 (4%)
Central/East Europe 339 (3%) 35  (5%)
Other/Unknown 760 (6%) 30 (4%)
Died during follow-up 7156 (61%) 515 (73%)1346 P Brennan et al
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Table 2 Observed and expected numbers of second primary cancers following a diagnosis of NHL, New South Wales, 1972–1995
Site Observed Expected SIR 95% confidence
(ICD9 code) interval
All neoplasms 705 592.99 1.19 (1.10–1.28)
Lip (140) 17 6.21 2.74 (1.59–4.38)
Tongue (141) 8 3.16 2.53 (1.09–4.99)
Salivary gland (142) 4 1.80 2.22 (0.60–5.70)
Mouth (143–145) 5 4.04 1.24 (0.40–2.89)
Pharynx (146–149) 6 4.68 1.28 (0.47–2.79)
Oesophagus (150) 13 8.9 1.45 (0.77–2.48)
Stomach (151) 18 23.00 0.78 (0.46–1.24)
Colon (153) 80 64.21 1.25 (0.99–1.55)
Rectum (154) 38 33.85 1.12 (0.79–1.54)
Liver (155) 4 2.95 1.35 (0.36–3.47)
Gallbladder (156) 4 5.57 0.72 (0.19–1.84)
Pancreas (157) 8 17.59 0.45 (0.20–0.90)
Nose, sinuses (160) 1 1.06 0.94 (0.01–5.25)
Larynx (161) 5 6.83 0.73 (0.24–1.71)
Lung (162) 83 82.36 1.01 (0.80–1.25)
Bone (170) 2 0.80 2.51 (0.30–9.04)
Soft tissue sarcoma (171) 11 3.05 3.61 (1.80–6.45)
Melanoma of skin (172) 93 39.13 2.38 (1.92–2.91)
Female breast (174) 46 51.10 0.90 (0.66–1.20)
Cervix uteri (180) 4 5.88 0.68 (0.18–1.74)
Corpus uteri (182) 9 8.52 1.06 (0.48–2.00)
Ovary (183) 9 7.74 1.16 (0.53–2.21)
Prostate (185) 84 81.98 1.02 (0.82–1.27)
Testis (186) 0 0.90 0 (0.00–4.10)
Bladder (188) 44 26.77 1.64 (1.19–2.21)
Kidney (189) 20 16.11 1.24 (0.76–1.92)
Brain, nervous stemem (191–192) 6 7.94 0.76 (0.28–1.64)
Thyroid (193) 9 2.63 3.42 (1.56–6.49)
Hodgkin’s disease (201) 2 1.67 1.20 (0.13–4.32)
Multiple myeloma (203) 5 7.96 0.63 (0.20–1.47)
Lymphoid leukaemia (204) 5 6.15 0.81 (0.26–1.90)
Myeloid leukaemia (205) 6 7.71 0.78 (0.28–1.69)
Other leukaemia (206–208) 3 2.39 1.26 (0.26–3.67)
Others 53 48.35 1.10 (0.82–1.43)
Sites in bold represent a statistically significant (P < 0.05) excess or deficit from the expected value.
Table 3 Observed and SIR for second primary neoplasms following NHL, New South Wales, 1972–1995, stratified by demographic characteristics
Lip cancer Tongue cancer Soft tissue sarcoma Melanoma of skin Bladder cancer Thyroid cancer
O SIR 95% Cl O SIR 95% Cl O SIR 95% Cl O SIR 95% Cl O SIR 95% Cl O SIR 95% Cl
Sex
Men 10 2.08 (1.0–3.8) 3 1.43 (0.3–4.2) 9 4.81 (2.2–9.1) 60 2.41 (1.8–3.1) 36 1.74 (1.2–2.4) 2 2.04 (0.2–7.4)
Women 7 4.95 (2.0–10) 5 4.72 (1.5–11) 2 1.70 (0.2–6.1) 33 2.31 (1.6–3.2) 8 1.31 (0.6–2.6) 7 4.24 (1.7–8.8)
Age at NHL
diagnosis <51 2 2.52 (0.3–9.1) 0 0 (0.0–8.6) 1 2.50 (0.1–14) 15 2.14 (1.2–3.5) 4 2.73 (0.7–7.0) 3 4.35 (0.9–12)
51–64 7 3.45 (1.4–7.1) 5 3.82 (1.2–8.9) 4 4.28 (1.1–11) 41 2.92 (2.1–4.0) 12 1.47 (0.8–2.6) 4 4.60 (1.2–11)
65–70 4 3.00 (0.8–7.7) 0 0 (0.0–5.5) 3 4.56 (0.9–13) 19 2.41 (1.5–3.8) 11 1.66 (0.8–3.0) 0 0 (0.0–8.2)
71+ 4 2.0 (0.5–5.0) 3 3.98 (0.8–12) 3 2.83 (0.6–8.3) 18 1.76 (1.0–2.8) 17 1.62 (0.9–2.6) 2 3.24 (0.4–12)
Year of diagnosis
1972–1979 3 1.50 (0.3–4.4) 2 1.93 (0.2–7.0) 2 2.11 (0.2–7.6) 26 2.39 (1.6–3.5) 15 1.56 (0.9–2.6) 4 4.83 (1.3–12)
1980–1984 4 2.72 (0.7–7.0) 3 3.76 (0.8–11) 2 2.84 (0.3–10) 27 2.77 (1.8–4.0) 11 1.61 (0.8–2.9) 2 3.07 (0.3–11)
1985–1989 7 4.24 (1.7–8.7) 2 2.44 (0.3–8.8) 5 5.96 (1.9–14) 25 2.22 (1.4–3.3) 11 1.73 (0.9–3.1) 2 2.83 (0.3–10)
1990–1995 3 2.73 (0.6–8.0) 1 1.96 (0.3–11) 2 3.56 (0.4–13) 15 2.07 (1.2–3.4) 7 1.76 (0.7–3.6) 1 2.25 (0.1–12)
Time period after
NHL diagnosis
4–12 months 1 1.14 (0.1–6.3) 1 2.19 (0.0–12) 1 2.38 (0.1–13) 13 2.44 (1.3–4.2) 5 1.30 (0.4–3.1) 0 0 (0.0–10)
1–4 years 10 3.77 (1.8–6.9) 4 2.85 (0.8–7.3) 6 4.62 (1.7–10) 34 2.04 (1.4–2.8) 21 1.82 (1.1–2.8) 3 2.59 (0.5–7.6)
5–9 years 4 2.63 (0.7–6.7) 2 2.51 (0.3–9.1) 4 5.28 (1.4–14) 33 3.32 (2.3–4.7) 10 1.50 (0.7–2.8) 2 2.99 (0.3–10)
10+ years 2 1.72 (0.2–6.2) 1 1.97 (0.3–11) 0 0 (0.0–6.7) 13 1.81 (1.0–3.1) 8 1.68 (0.7–3.3) 4 9.29 (2.5–24)
Country of origin
Oceania 15 3.20 (1.8–5.3) 7 2.91 (1.2–6.0) 8 3.44 (1.5–6.8) 75 2.52 (2.0–3.2) 32 1.58 (1.1–2.2) 9 4.44 (2.0–8.4)
North/West Europe1 1.39 (0.1–7.7) 1 2.87 (0.0–16) 1 2.89 (0.1–16) 10 2.37 (1.1–4.4) 7 2.15 (0.9–4.4) 0 0 (0.0–13)
Med Europe 0 0 (0.0–17) 0 0 (0.0–31) 2 19.6 (2.2–71) 0 0 (0.2–53) 1 1.22 (0.1–6.8) 0 0 (0.0–41)
Cent/East Europe 0 0 (0.0–18) 0 0 (0.0–18) 0 0 (0.0–37) 1 0.82 (0.1–4.6) 3 3.2 (0.6–9.3) 0 0 (0.0–53)
Other* 1 2.64 (0.1–14) 0 0 (0.0–19) 0 0 (0.0–21) 7 2.8 (1.1–5.6) 1 0.68 (0.0–3.8) 0 0 (0.0–23)
O = Observed, SIR = standardized incidence ratio, Other* = Asia/Middle East/Americas/Africa/Unknown.Second primary neoplasms after NHL 1347
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likely to be related to radiotherapy (Ron, 1996). This excess was
most apparent 10 years after the initial diagnosis of NHL, and is
thus consistent with a late effect of treatment. Interestingly, we did
not observe any excess for leukaemia as a whole or myeloid
leukaemia in particular as a second cancer, in contrast to the large
excesses observed in previous studies (Boffetta et al, 1999). The
increase in ANLL observed in other cohorts is assumed to be due
to one or more components of MOPP chemotherapy regimes
(mechlorethamine, vincristine, procarbazine and prednisone), and
possibly radiation therapy (Travis et al, 1991). It is possible that
the implementation of treatment regimes for NHL may have been
different in New South Wales over the study period compared to
the USA. Moreover, the SIR for leukaemia, and for myeloid
leukaemia in particular, was close to 1.0 for all calendar periods,
and also all time periods after diagnosis of NHL (data not shown).
This would also indicate that changes over time in the coding of
ANLL cannot explain the absence of an association.
The joint association between NHL and melanoma of the skin
has previously been hypothesized to be due to solar ultraviolet
radiation (McMichael and Giles, 1996; Cartwright et al, 1994),
although another shared cause acting through an immunosuppres-
sive effect is possible. The observed increase in cancer of the lip
after NHL, which has not been previously noted, supports the
suggestion of a shared effect of sun exposure. Although expected
numbers were small, no cases of melanoma of the skin or lip
cancer were observed among migrants from Mediterranean
Europe, who, due to their darker complexion, are less susceptible
to ultraviolet associated cancers than most people born in
Australia or Northern or Western Europe (Scotto et al, 1996).
These data do however need to be interpreted cautiously as infor-
mation on country of birth for melanoma of the skin is available on
only 47% of cases registered in NSW. The increase in tongue
cancer may also be related to sunlight exposure. Although cancer
of the tongue is not normally considered to be an ultraviolet
related neoplasm, there is over a 1000-fold increase in tongue
cancer among patients with xeroderma pigmentosum, a rare
inherited cancer-prone DNA repair disorder due to marked hyper-
sensitivity to ultraviolet light (Kraemer et al, 1994). These
cancers tend to be restricted to the tip of the tongue. Information
on subsite of the tongue in the current study was recorded for only
four of the eight cases. Two of these cases were recorded as base
of the tongue and two were recorded as tip of the tongue. The
increase in soft tissue sarcomas might support the view that NHL
and soft tissue sarcomas are both associated with exposure to
chemicals such as phenoxy acid herbicides (Kogevinas et al,
1997).
In summary, we have confirmed the association between NHL
and melanoma of the skin, which may be explained by joint
exposure to solar ultraviolet radiation. We have also identified an
excess of lip and tongue cancer after NHL which might be
explained by the same relationship. Our results provide support
for sunlight exposure as a cause of the increasing incidence of
NHL.
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